Novo Nordisk Revamps Leadership with Key Appointments in the U.S. Operations
Novo Nordisk appoints Jamey Millar as U.S. business head and Hong Chow as product and portfolio strategy lead. Millar, who previously worked at UnitedHealth Group, will succeed Dave Moore on February 5. Chow, from Merck Healthcare, replaces Ludovic Helfgott starting February 15.
Novo Nordisk, renowned for its pharmaceutical contributions, has announced pivotal changes in its leadership structure within the United States. Jamey Millar has been designated as the new head of U.S. operations, with his tenure commencing on February 5. Millar previously served as CEO of Optum Specialty Holdings at UnitedHealth Group.
In addition to this, Hong Chow will spearhead product and portfolio strategy at Novo Nordisk, stepping into her new role on February 15. Chow transitions from Merck Healthcare in Germany, adding a global perspective to the company's strategic endeavors.
These appointments are part of Novo Nordisk's ongoing efforts to strengthen its strategic positioning in the pharmaceutical market, especially following the success of their weight-loss drug, Wegovy.
ALSO READ
-
Wegovy Woes: Novo Nordisk Faces Profit Slump Amid Fierce Competition
-
Leadership Shuffle at Novo Nordisk: A Strategic Shift
-
Leadership Changes at Novo Nordisk: A Strategic Move
-
Novo Nordisk Boosts Shareholder Return with New Repurchase Program
-
Novo Nordisk Fights to Reclaim Obesity Drug Market Amid Declining Sales
Google News